You can buy or sell Cytosorbents and other stocks, options, ETFs, and crypto commission-free!
CytoSorbents Corp. engages in the research and development of blood purification technology for the reduction of deadly uncontrolled inflammation in hospitalized patients. Its product include CytoSorb, ContrastSorb, HemoDefend, VetResQ, and DrugSorb. Read More The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Monmouth Junction, NJ.
Monmouth Junction, New Jersey
52 Week High
52 Week Low
The Motley FoolMar 7
Cytosorbents Corp (CTSO) Q4 2018 Earnings Conference Call Transcript
Cytosorbents Corp (NASDAQ:CTSO) Q4 2018 Earnings Conference Call , 4:45 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good afternoon, and welcome to the CytoSorbents 2018 Financial and Operating Results Conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request. At this time, I'd like...
Markets InsiderMar 7
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2018
MONMOUTH JUNCTION, N.J., March 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, achieves record total revenue, CytoSorb® sales, and product gross margins in 2018. 2018 Financial Highlights: Full year 2018 total revenue was $22.5 million , including both product sales and grant income, a 49% increase fro...
Expected May 7, After Hours